Advocacy intelligence hub — real-time data for patient organizations
M.D. Anderson Cancer Center — PHASE1
Washington University School of Medicine — PHASE1, PHASE2
Shenzhen Geno-Immune Medical Institute — PHASE1, PHASE2
Nationwide Children's Hospital — PHASE2
Nationwide Children's Hospital — PHASE2
OX2 Therapeutics — PHASE1
Chulalongkorn University — PHASE1
Rigshospitalet, Denmark — NA
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Modeyso
(dordaviprone)Orphan drugChimerix, Inc.
12.1 Mechanism of Action Dordaviprone is a protease activator of the mitochondrial caseinolytic protease P (ClpP). Dordaviprone also inhibits the dopa...
Eric Bouffet, MD
The Hospital for Sick Children
📍 Los Angeles, California
Sabine Mueller, MD, MD, PhD
University of California, San Francisco
📍 SAN FRANCISCO, CA
Maryam Fouladi, MD, MD
Nationwide Children's Hospital
📍 COLUMBUS, OH
Ute Bartels, MD
The Hospital for Sick Children
Stergios Zacharoulis, MD, MD
Columbia University
📍 LONDON, UK
Mark Souweidane, MD, MD
Memorial Sloan Kettering Cancer Center
📍 NEW YORK, NY